# Expression Therapeutics

Source: https://onco.cc/companies/expression-therapeutics/  
OnCo record `expression-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Expression Therapeutics, near Atlanta, makes cell and gene therapies. In cancer it programmes a patient's gamma-delta T cells to release a protein that pulls other immune cells onto the tumour, starting with neuroendocrine tumours.

## Summary

Expression Therapeutics, Inc., headquartered in Tucker, Georgia, with manufacturing in West Chester Township, Ohio, develops gene therapies for haemophilia A and cell therapies for cancer. Its ADEPT-STAR approach expands a patient's own gamma-delta T cells and programmes them with its LENTeT gene transfer system to secrete a T-cell engager. The lead, ADEPT-STAR-NET-1, secretes a CD3 by SSTR2 bispecific engager for gastroenteropancreatic neuroendocrine tumours and is preclinical. A 2026 National Cancer Institute SBIR award funds ADEPT-STAR therapy for high-risk neuroblastoma.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Expression Therapeutics, Inc.
- HQ: Tucker, GA
- Type: cell-therapy
- Website: https://www.expressiontherapeutics.com/

## Notes

- Company website (home and neuroendocrine tumour pages) and the NIH RePORTER record read on 4 November 2026. The target used for neuroblastoma is not stated in the parts of the award read.

## Sources

- Official website: https://www.expressiontherapeutics.com/
- Neuroendocrine tumour programme: https://www.expressiontherapeutics.com/therapeutics-nets
- NIH RePORTER: award 2R44CA281633-02A1: https://reporter.nih.gov/project-details/11407954

## Connected records

- cancers: [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Gamma-delta T cell therapy](https://onco.cc/technologies/gamma-delta-t-cell-therapy/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [Somatostatin receptor 2](https://onco.cc/targets/sstr2/)
- drugs: [ADEPT-STAR-NET-1](https://onco.cc/drugs/adept-star-net-1/)

---
JSON: https://onco.cc/api/v1/entities/expression-therapeutics.json